Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: A hypothesis

American Journal of Kidney Diseases

Volumn 62, Issue 5, 2013, Pages 984-992

  Cozzolino, Mario ^a   Gentile, Giorgio ^b,c   Mazzaferro, Sandro ^d   Brancaccio, Diego ^e   Ruggenenti, Piero ^b,c   Remuzzi, Giuseppe ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Renal Unit Simone Martini   (Italy)

Author keywords

blood pressure; Chronic kidney disease; phosphate; proteinuria; vitamin D deficiency

Indexed keywords

AMLODIPINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIVALENT CATION; FELODIPINE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; METOPROLOL; PHOSPHATE; PHOSPHATE BINDING AGENT; RAMIPRIL; VITAMIN D DERIVATIVE;

ADD ON THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOTHESIS; MINERAL METABOLISM; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; TREATMENT PLANNING; VITAMIN D DEFICIENCY;

EID: 84886724624     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.02.379     Document Type: Review

References (106)

1. W.G. Couser, G. Remuzzi, S. Mendis, M. Tonelli The contribution of chronic kidney disease to the global burden of major noncommunicable diseases Kidney Int 80 12 2011 1258 1270
2. International Society of Nephrology A briefing on the global impact of kidney disease. 2011 http://www.theisn.org/images/stories/WHO-CKD-Brochure-LR. pdf Accessed February 15, 2013
3. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 31 2004 1296 1305
4. E. Wuhl, F. Schaefer Medscape Managing kidney disease with blood-pressure control Nat Rev Nephrol 7 8 2011 434 444
5. M. Rahman, S. Pressel, B.R. Davis Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate Ann Intern Med 144 3 2006 72 180
6. P. Ruggenenti, A. Perna, L. Mosconi, R. Pisoni, G. Remuzzi Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN) Kidney Int 53 5 1998 1209 1216
7. D. de Zeeuw, G. Remuzzi, H.H. Parving Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 8 2004 921 927
8. World Health Organization Global health risks: mortality and burden of disease attributable to selected major risks. 2009 http://www.who.int/ healthinfo/global-burden-disease/GlobalHealthRisks-report-part2.pdf Accessed February 15, 2013
9. M. Paul, A. Poyan Mehr, R. Kreutz Physiology of local renin-angiotensin systems Physiol Rev 86 3 2006 747 803
10. M.J. Klag, P.K. Whelton, B.L. Randall Blood pressure and end-stage renal disease in men N Engl J Med 334 1 1996 13 18
11. M. Tozawa, K. Iseki, C. Iseki, K. Kinjo, Y. Ikemiya, S. Takishita Blood pressure predicts risk of developing end-stage renal disease in men and women Hypertension 41 6 2003 1341 1345
12. P. Cravedi, P. Ruggenenti, G. Remuzzi Which antihypertensive drugs are the most nephroprotective and why? Expert Opin Pharmacother 11 16 2010 2651 2663
13. S. Klahr, A.S. Levey, G.J. Beck The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease Modification of Diet in Renal Disease Study Group N Engl J Med 330 13 1994 877 884
14. R.D. Toto, H.C. Mitchell, R.D. Smith, H.C. Lee, D. McIntire, W.A. Pettinger "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis Kidney Int 48 3 1995 851 859
15. J.T. Wright, G. Bakris, T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 19 2002 2421 2431
16. P. Ruggenenti, A. Perna, G. Loriga Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial Lancet 365 9463 2005 939 946
17. J.C. Peterson, S. Adler, J.M. Burkart Blood pressure control, proteinuria, and the progression of renal disease The Modification of Diet in Renal Disease Study Ann Intern Med 123 10 1995 754 762
18. British Renal Association Society Guidelines Detection, monitoring and care of patients with CKD. 2011 http://www.renal.org/Clinical/GuidelinesSection/ Detection-Monitoring-and-Care-of-Patients-with-CKD.aspx Accessed February 15, 2013
19. S. Anderson, T.W. Meyer, H.G. Rennke, B.M. Brenner Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass J Clin Invest 76 2 1985 612 619
20. O. Deyneli, D. Yavuz, A. Velioglu Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients J Renin Angiotensin Aldosterone Syst 7 2 2006 98 103
21. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy The Collaborative Study Group N Engl J Med 329 20 1993 1456 1462
22. K. Matsushita, M. van der Velde, B.C. Astor Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 9731 2010 2073 2081
23. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet 349 9069 1997 1857 1863
24. P. Hovind, P. Rossing, L. Tarnow, H. Toft, J. Parving, H.H. Parving Remission of nephrotic-range albuminuria in type 1 diabetic patients Diabetes Care 24 11 2001 1972 1977
25. R.C. Atkins, E.M. Briganti, J.B. Lewis Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy Am J Kidney Dis 45 2 2005 281 287
26. W.F. Keane, Z. Zhang, P.A. Lyle Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL Study Clin J Am Soc Nephrol 1 4 2006 761 767
27. G. Remuzzi, A. Benigni, A. Remuzzi Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes J Clin Invest 116 2 2006 288 296
28. H.H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 12 2001 870 878
29. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
30. G. Maschio, D. Alberti, G. Janin Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 15 1996 939 945
31. P. Cravedi, P. Ruggenenti, G. Remuzzi Proteinuria should be used as a surrogate in CKD Nat Rev Nephrol 8 5 2012 301 306
32. G. Remuzzi, P. Ruggenenti, A. Benigni Understanding the nature of renal disease progression Kidney Int 51 1 1997 2 15
33. A.S. Levey, P.E. de Jong, J. Coresh The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report Kidney Int 80 1 2011 17 28
34. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 9731 2010 2073 2081
35. K. Iseki, C. Iseki, Y. Ikemiya, K. Fukiyama Risk of developing end-stage renal disease in a cohort of mass screening Kidney Int 49 3 1996 800 805
36. K. Iseki, Y. Ikemiya, C. Iseki, S. Takishita Proteinuria and the risk of developing end-stage renal disease Kidney Int 63 4 2003 1468 1474
37. A. Ishani, G.A. Grandits, R.H. Grimm Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial J Am Soc Nephrol 17 5 2006 1444 1452
38. R. Retnakaran, C.A. Cull, K.I. Thorne, A.I. Adler, R.R. Holman UKPDS Study Group Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 Diabetes 55 6 2006 1832 1839
39. P. Ruggenenti, A. Perna, G. Remuzzi GISEN Group Investigators Retarding progression of chronic renal disease: the neglected issue of residual proteinuria Kidney Int 63 6 2003 2254 2261
40. T. Ninomiya, V. Perkovic, C. Verdon Proteinuria and stroke: a meta-analysis of cohort studies Am J Kidney Dis 53 3 2009 417 425
41. A.K. Bello, B. Hemmelgarn, A. Lloyd Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes Clin J Am Soc Nephrol 6 6 2011 1418 1426
42. S.I. Hallan, E. Ritz, S. Lydersen, S. Romundstad, K. Kvenild, S.R. Orth Combining GFR and albuminuria to classify CKD improves prediction of ESRD J Am Soc Nephrol 20 5 2009 1069 1077
43. M. van der Velde, K. Matsushita, J. Coresh Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality A collaborative meta-analysis of high-risk population cohorts Kidney Int 79 12 2011 1341 1352
44. H. Myrvang Progression of renal disease: high salt intake blunts the benefit of ACE inhibitors and accelerates renal function decline Nat Rev Nephrol 8 2 2012 61
45. P. Ruggenenti, A. Perna, M. Tonelli Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial Clin J Am Soc Nephrol 5 11 2010 1928 1938
46. C. Zoja, D. Corna, D. Camozzi How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach J Am Soc Nephrol 13 12 2002 2898 2908
47. P. Ruggenenti, E. Perticucci, P. Cravedi Role of remission clinics in the longitudinal treatment of CKD J Am Soc Nephrol 19 6 2008 1213 1224
48. E. Daina, S. Gamba, P. Ruggenenti Effects of the remission clinic approach in Alport syndrome: results from a prospective, sequential cohort study. American Society of Nephrology (ASN) Kidney Week. 2012 https://www.asn-online.org/scripts/download.aspx?file=/education/kidneyweek/ archives/KW12Abstracts.pdf Accessed February 15, 2013
49. L.S. Ibels, A.C. Alfrey, L. Haut, W.E. Huffer Preservation of function in experimental renal disease by dietary restriction of phosphate N Engl J Med 298 3 1978 122 126
50. G. Barsotti, E. Morelli, A. Giannoni, A. Guiducci, S. Lupetti, S. Giovannetti Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: a controlled trial Kidney Int Suppl 16 1983 S278 S284
51. C. Zoccali, P. Ruggenenti, A. Perna Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition J Am Soc Nephrol 22 10 2011 1923 1930
52. G.B. John, C.Y. Cheng, M. Kuro-o Role of klotho in aging, phosphate metabolism, and CKD Am J Kidney Dis 58 1 2011 127 134
53. J. Uribarri, M.S. Calvo Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 16 3 2003 186 188
54. T. Isakova, O.M. Gutierrez, K. Smith Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease Nephrol Dial Transplant 26 2 2011 584 591
55. S.M. Moe, M.P. Zidehsarai, M.A. Chambers Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease Clin J Am Soc Nephrol 6 2 2011 257 264
56. 3 and phosphorus in vivo J Biol Chem 80 4 2005 2543 2549
57. E. Shuto, Y. Taketani, R. Tanaka Dietary phosphorus acutely impairs endothelial function J Am Soc Nephrol 20 7 2009 1504 1512
58. A. Martin, V. David, L.D. Quarles Regulation and function of the FGF23/klotho endocrine pathways Physiol Rev 92 1 2012 131 155
59. M. Wolf Update on fibroblast growth factor 23 in chronic kidney disease Kidney Int 82 7 2012 737 747
60. S. Liu, W. Tang, J. Zhou Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D J Am Soc Nephrol 17 5 2006 1305 1315
61. J. Gattineni, C. Bates, K. Twombley FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 Am J Physiol Renal Physiol 297 2 2009 F282 F291
62. M.I. Yilmaz, A. Sonmez, M. Saglam FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease Kidney Int 78 7 2010 679 685
63. Y.C. Li, J. Kong, M. Wei, Z.F. Chen, S.Q. Liu, L.P. Cao 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system J Clin Invest 110 2 2002 229 238
64. M.H. De Borst, M.G. Vervloet, P.M. Ter Wee, G. Navis Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease J Am Soc Nephrol 22 9 2011 1603 1609
65. J. Kendrick, A.K. Cheung, J.S. Kaufman FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis J Am Soc Nephrol 22 10 2011 1913 1922
66. C. Faul, A.P. Amaral, B. Oskouei FGF23 induces left ventricular hypertrophy J Clin Invest 121 11 2011 4393 4408
67. V. Lavi-Moshayoff, G. Wasserman, T. Meir, J. Silver, T. Naveh-Many PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop Am J Physiol Renal Physiol 299 4 2010 F882 F889
68. A. Dusso, M.V. Arcidiacono, J. Yang, M. Tokumoto Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality J Steroid Biochem Mol Biol 121 1-2 2010 193 198
69. J.A. Moreno, M.C. Izquierdo, M.D. Sanchez-Nino The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB J Am Soc Nephrol 22 7 2011 1315 1325
70. H. Mitani, N. Ishizaka, T. Aizawa In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage Hypertension 39 4 2002 838 843
71. R.A. Black, C.T. Rauch, C.J. Kozlosky A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 6618 1997 729 733
72. W.B. Melenhorst, L. Visser, A. Timmer, M.C. van den Heuvel, C.A. Stegeman, H. van Goor ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol Renal Physiol 297 3 2009 F781 F790
73. A. Dusso, E.A. Gonzalez, K.J. Martin Vitamin D in chronic kidney disease Best Pract Res Clin Endocrinol Metab 25 4 2011 647 655
74. A.S. Dusso Renal vitamin D receptor expression and vitamin D renoprotection Kidney Int 81 10 2012 937 939
75. E.J. Weil, K.V. Lemley, C.C. Mason Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy Kidney Int 82 9 2012 1010 1017
76. G. Remuzzi, T. Bertani Pathophysiology of progressive nephropathies N Engl J Med 339 20 1998 1448 1456
77. P. Ruggenenti, P. Cravedi, G. Remuzzi Mechanisms and treatment of CKD J Am Soc Nephrol 23 12 2012 1917 1928
78. C. Zoja, M. Morigi, M. Figliuzzi Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins Am J Kidney Dis 26 6 1995 934 941
79. K. Drumm, B. Bauer, R. Freudinger, M. Gekle Albumin induces NF-kappaB expression in human proximal tubule-derived cells (IHKE-1) Cell Physiol Biochem 12 4 2002 187 196
80. S. Tang, J.C. Leung, K. Abe Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo J Clin Invest 111 4 2003 515 527
81. M. Abbate, C. Zoja, G. Remuzzi How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17 11 2006 2974 2984
82. J.L. Barnes, Y. Gorin Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases Kidney Int 79 9 2011 944 956
83. D.W. Johnson, H.J. Saunders, R.C. Baxter, M.J. Field, C.A. Pollock Paracrine stimulation of human renal fibroblasts by proximal tubule cells Kidney Int 54 3 1998 747 757
84. L. Biancone, S. David, V. Della Pietra, G. Montrucchio, V. Cambi, G. Camussi Alternative pathway activation of complement by cultured human proximal tubular epithelial cells Kidney Int 45 2 1994 451 460
85. M. Nangaku, J. Pippin, W.G. Couser Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome J Am Soc Nephrol 10 11 1999 2323 2331
86. G.K. Rangan, J.W. Pippin, J.D. Coombes, W.G. Couser C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria Kidney Int 67 2 2005 492 503
87. H.J. Kim, N.D. Vaziri Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure Am J Physiol Renal Physiol 298 3 2010 F662 F671
88. D. Laouari, M. Burtin, A. Phelep A transcriptional network underlies susceptibility to kidney disease progression EMBO Mol Med 4 8 2012 825 839
89. B. Rodriguez-Iturbe, N.D. Vaziri, J. Herrera-Acosta, R.J. Johnson Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all Am J Physiol Renal Physiol 286 4 2004 F606 F616
90. M. Cozzolino, Y. Lu, J. Finch, E. Slatopolsky, A.S. Dusso p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium Kidney Int 60 6 2001 2109 2117
91. A. Lautrette, S. Li, R. Alili Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach Nat Med 11 8 2005 867 874
92. W. Xiang, J. Kong, S. Chen Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems Am J Physiol Endocrinol Metab 288 1 2005 E125 E132
93. N. Bodyak, J.C. Ayus, S. Achinger Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals Proc Natl Acad Sci U S A 104 43 2007 16810 16815
94. 3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat Am J Physiol Renal Physiol 286 3 2004 F526 F533
95. W. He, Y.S. Kang, C. Dai, Y. Liu Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury J Am Soc Nephrol 22 1 2011 90 103
96. W.L. Lau, E.M. Leaf, M.C. Hu Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet Kidney Int 82 12 2012 1261 1270
97. M. Wolf, A. Shah, O. Gutierrez Vitamin D levels and early mortality among incident hemodialysis patients Kidney Int 72 8 2007 1004 1013
98. D. de Zeeuw, R. Agarwal, M. Amdahl Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial Lancet 376 9752 2010 1543 1551
99. J. Cheng, W. Zhang, X. Zhang, X. Li, J. Chen Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis Clin J Am Soc Nephrol 7 3 2012 391 400
100. P. Alborzi, N.A. Patel, C. Peterson Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial Hypertension 52 2 2008 249 255
101. S. Fishbane, H. Chittineni, M. Packman, P. Dutka, N. Ali, N. Durie Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial Am J Kidney Dis 54 4 2009 647 652
102. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 8 2004 2208 2218
103. B. Kestenbaum, J.N. Sampson, K.D. Rudser Serum phosphate levels and mortality risk among people with chronic kidney disease J Am Soc Nephrol 16 2 2005 520 528
104. J.H. Ix, M.G. Shlipak, C.L. Wassel, M.A. Whooley Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study Nephrol Dial Transplant 25 3 2010 993 997
105. M. Cozzolino, M.E. Staniforth, H. Liapis Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia Kidney Int 64 5 2003 1653 1661
106. M. Cozzolino, A.S. Dusso, H. Liapis The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats J Am Soc Nephrol 13 9 2002 2299 2308